Posts by Mourabit Halima

 Diffuse large B-cell lymphoma (DLBCL) is a typical B-cell lymphoma, characterized by high invasiveness and heterogeneity. After standard first-line treatment, some patients still face relapse/refractory issues and relatively poor prognosis. Recently, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum" was successfully held in Beijing from March 1st to 3rd, 2024. After the conference, Oncology Frontier - Hematology Frontier specially invited Professor Jun Zhu from Peking University Cancer Hospital to share the unmet needs of DLBCL patients and their treatment strategies.

Thrombocytopenia is a common hematologic adverse reaction to cancer treatment, which can increase the risk of bleeding, prolong hospitalization, increase medical costs, and in severe cases, lead to death. Recently, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum", hosted by the Chinese Society of Immunology Hematology Branch and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology and Beijing Hospital of Peking University, was held successfully in Beijing from March 1st to 3rd, 2024. After the conference, Oncology Frontier - Hematology Frontier invited Professor Hu Zhou from Henan Cancer Hospital to share the diagnosis and treatment progress of tumor-related thrombocytopenia.

The "7th Beijing Thrombosis and Hemostasis Conference of the Chinese Society of Immunology Hematology Branch" and the "5th Beijing Hematologic Tumor and Immunology Summit Forum" sponsored by the Chinese Society of Immunology Hematology Branch and hosted by the National Clinical Research Center for Hematologic Diseases- Peking University Institute of Hematology and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was held in Beijing from March 1st to 3rd, 2024. During the conference, Oncology Frontier - Hematology Frontier had the honor to invite Professor Jun Ma from the Harbin Institute of Hematology and Oncology to share the development process of hematology in recent decades and advances in the treatment of hematologic tumors.

As spring arrives, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference focused comprehensively on hematopoietic stem cell transplantation, bringing together many renowned experts in the field of hematology from both domestic and international arenas. Centered around the basic and clinical research of hematopoietic stem cell transplantation, the conference covered various topics including advancements in transplantation indications, new transplantation models, prevention and treatment strategies for transplantation complications and relapse, progress in basic research, and transplantation-related clinical trials. During the conference, Oncology Frontier - Hematology Frontier had the honor to interview Professor Xiaohui Zhang from Peking University People's Hospital, who shared the significant progress made in the field of hematopoietic stem cell transplantation in China in recent years.

 Acute graft-versus-host disease (aGVHD) is a severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a major cause of non-relapse mortality in patients with hematologic malignancies. Although treatment options for aGVHD have advanced in recent years, the prognosis remains poor. Recently, the "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was held from March 1st to 3rd, 2024, in Beijing. Following the conference, Oncology Frontier - Hematology Frontier had the honor of inviting Professor Erjie Jiang, Director of the Stem Cell Transplantation Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science, to share insights on the challenges, risk factors, and diagnostic and therapeutic advances in acute graft-versus-host disease (aGVHD).

From March 1st to 2nd, 2024, the "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was grandly held in Beijing. Many renowned experts and scholars in the field of hematology gathered to share and exchange insights on topics such as the basics and clinical research of hematopoietic stem cell transplantation, advancements in transplantation indications, new transplantation modalities, prevention and treatment strategies for transplant complications and relapse, progress in basic research, and transplantation-related clinical trials. During the conference, Oncology Frontier - Hematology Frontier was honored to invite Professor Qifa Liu  from the Department of Hematology at Southern Medical University Nanfang Hospital to conduct in-depth discussions on topics such as "Clinical Research Design and Registration Standards" and standardization of hematologic tumor treatment. The following is a summary of the discussion.

Severe coagulopathy poses a serious threat to human life and health, with disseminated intravascular coagulation (DIC) being a common severe coagulopathy characterized by rapid development, dangerous progression, and high mortality. In recent years, Professor Ben Lv from the Second Xiangya Hospital of Central South University has conducted a series of original research studies on the pathogenesis and targeted intervention of sepsis, discovering that the HMGB1-Caspase11 pathway mediates the immune response, which is a critical link leading to DIC, organ failure, and death in sepsis. This research provides potential biomarkers and drug intervention targets for the diagnosis and treatment of sepsis and has been published in internationally renowned academic journals such as Science, Nature, Immunity, Nature Communications, and Blood. At the just-concluded 13th National Conference on Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association, Professor Ben Lv delivered a brilliant report on "The Basic and Clinical Research of Severe Coagulopathy" and "Infection and DIC," summarizing breakthrough research achievements in recent years in the fields of severe coagulopathy and sepsis, providing new directions for the development of diagnosis and treatment of severe coagulopathy. Oncology Frontier - Hematology Frontier hereby compiles and presents it for readers.

In the bright spring of March, various flowers are blooming. The "13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association," hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology, was grandly held from March 1st to 2nd in Beijing. Hematopoietic stem cell transplantation is an important means of treating various hematologic diseases, and it is currently the most vigorous field in hematology at home and abroad. China's hematopoietic stem cell transplantation has also achieved remarkable results internationally, especially the "Beijing Protocol" established by Academician Xiaojun Huang, Director of Peking University Institute of Hematology and one of the chairpersons of this conference, has made outstanding contributions to the field of hematopoietic stem cell transplantation. This conference focused comprehensively on hematopoietic stem cell transplantation and conducted academic discussions from various aspects and forms. During the conference, Oncology Frontier - Hematology Frontier had the honor of inviting Academician Xiaojun Huang to share insights into the creation of the "Beijing Protocol" and point out the urgent problems and future directions in the field of hematopoietic stem cell transplantation.

With the arrival of spring, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the National Clinical Research Center for Hematologic Diseases and organized by Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference centered around the basic and clinical research of hematopoietic stem cell transplantation, covering multiple themes. During the conference, Oncology Frontier - Hematology Frontier had the honor to invite Professor Depei Wu from the First Affiliated Hospital of Soochow University for an interview, sharing challenges in the medical and health field and hopes for the younger generation.

In 2022, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology, was published in the prestigious Journal of Hematology & Oncology. The study is titled "Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial." This research marks a pivotal advancement in the treatment of chronic myeloid leukemia (CML), particularly for patients harboring the T315I mutation, underscoring the potential of precision medicine in the fight against this challenging disease.